Auriga Gives Buy Rating to Perrigo (PRGO)
Shares of Perrigo opened at 100.80 on Wednesday. Perrigo has a 52 week low of $75.89 and a 52 week high of $108.60. The company has a market cap of $9.415 billion and a P/E ratio of 25.08.
Perrigo last announced its earnings results on Tuesday, May 8th. The company reported $1.41 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.22 by $0.19. The company’s quarterly revenue was up 12.5% on a year-over-year basis. On average, analysts predict that Perrigo will post $1.24 earnings per share next quarter.
Several other analysts have also recently commented on the stock. Analysts at Needham & Company reiterated a “hold” rating on shares of Perrigo in a research note to investors on Wednesday. Separately, analysts at Deutsche Bank (NYSE: DB) cut their price target on shares of Perrigo from $103.00 to $101.00 in a research note to investors on Wednesday. They now have a “hold” rating on the stock. Finally, analysts at Caris & Company downgraded shares of Perrigo from a “buy” rating to an “average” rating in a research note to investors on Thursday, April 19th.
Perrigo Company is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, infant formulas, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products.